- Home
- VALU vs SAGE Comparison
VALU vs SAGE Comparison
Compare VALU & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALU
- SAGE
- Stock Information
- Founded
- VALU 1931
- SAGE 2010
- Country
- VALU United States
- SAGE United States
- Employees
- VALU N/A
- SAGE N/A
- Industry
- VALU Investment Managers
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- VALU Finance
- SAGE Health Care
- Exchange
- VALU Nasdaq
- SAGE Nasdaq
- Market Cap
- VALU 530.8M
- SAGE 462.2M
- IPO Year
- VALU N/A
- SAGE 2014
- Fundamental
- Price
- VALU $54.40
- SAGE $5.10
- Analyst Decision
- VALU
- SAGE Hold
- Analyst Count
- VALU 0
- SAGE 20
- Target Price
- VALU N/A
- SAGE $12.89
- AVG Volume (30 Days)
- VALU 11.3K
- SAGE 822.5K
- Earning Date
- VALU 12-13-2024
- SAGE 10-29-2024
- Dividend Yield
- VALU 2.21%
- SAGE N/A
- EPS Growth
- VALU 8.76
- SAGE N/A
- EPS
- VALU 2.13
- SAGE N/A
- Revenue
- VALU $36,628,000.00
- SAGE $106,399,000.00
- Revenue This Year
- VALU N/A
- SAGE N/A
- Revenue Next Year
- VALU N/A
- SAGE $118.26
- P/E Ratio
- VALU $25.58
- SAGE N/A
- Revenue Growth
- VALU N/A
- SAGE 837.60
- 52 Week Low
- VALU $36.00
- SAGE $5.03
- 52 Week High
- VALU $58.45
- SAGE $28.26
- Technical
- Relative Strength Index (RSI)
- VALU 60.41
- SAGE 28.88
- Support Level
- VALU $49.43
- SAGE $5.86
- Resistance Level
- VALU $57.68
- SAGE $5.87
- Average True Range (ATR)
- VALU 1.97
- SAGE 0.51
- MACD
- VALU 0.32
- SAGE -0.14
- Stochastic Oscillator
- VALU 66.29
- SAGE 1.91
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under well-known brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and The Most Trusted Name in Investment Research. Its only operating segment being Publishing.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.